Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (4198)	8/16/1999 2:05:00 PM
From: Kingfisher	Read Replies (2) \| Respond to of 4891

TO ALL regarding ADVR patent application for Reticulose as a product. To me this particular patent application indicates that Dr. Hirschman and his crew have finally determined the "so called" active ingredient(s) for Reticulose. Coupling this with the expenditure of approximately $75,000 to prepare the Bahamas manufacturing facility for FDA inspection further indicates to me that ADVR is closer then ever to the submission of the FDA IND application . As an aside regarding distributors. Doing a "page find" on the new 10Q for "DCT" resulted in a number of hits but doing a "page find" for "Commonwealth" or "AVIX" resulted in zero hits. This further indicates to me that conditions may now be far more palatable for joint ventures.